Table 3.
Baseline patient characteristics for all trials by age (n = 9679)
| Age at study entry (years) | ||||
|---|---|---|---|---|
|
| ||||
| Characteristic | <65 (N = 8234) |
≥65 (N = 1445) |
Total (N = 9679) |
p value |
| Race | 0.0234b | |||
| White | 6838 (83.0%) | 1247 (86.3%) | 8085 (83.5%) | |
| Black | 879 (10.7%) | 126 (8.7%) | 1005 (10.4%) | |
| Asian/Hawaiian/American Indian/Indian Subcontinent | 198 (2.4%) | 27 (1.9%) | 225 (2.3%) | |
| Other/missing/unknown/Hispanic American | 319 (3.9%) | 45 (3.1%) | 364 (3.8%) | |
| Ethnicity | 0.5845b | |||
| Hispanic/Latino | 386 (4.7%) | 63 (4.4%) | 449 (4.6%) | |
| Non-Hispanic/not reported/unknown | 7848 (95.3%) | 1382 (95.6%) | 9230 (95.4%) | |
| ECOG performance status | <0.0001b | |||
| 0 | 3047 (37.0%) | 851 (58.9%) | 3898 (40.3%) | |
| 1 | 356 (4.3%) | 235 (16.3%) | 591 (6.1%) | |
| 2 | 0 (0.0%) | 15 (1.0%) | 15 (0.2%) | |
| Missing | 4831 (58.7%) | 344 (23.8%) | 5175 (53.5%) | |
| Insurance | <0.0001b | |||
| Private | 6630 (80.5%) | 216 (14.9%) | 6846 (70.7%) | |
| Medicaid based | 615 (7.5%) | 83 (5.7%) | 698 (7.2%) | |
| Medicare/military/vet sponsored | 331 (4.0%) | 1063 (73.6%) | 1394 (14.4%) | |
| Other/missing | 658 (8.0%) | 83 (5.7%) | 741 (7.7%) | |
| Body surface areaa | 0.3748c | |||
| N | 8122 | 1437 | 9559 | |
| Mean (standard deviation) | 1.8 (0.2) | 1.8 (0.2) | 1.8 (0.2) | |
| Median | 1.8 | 1.8 | 1.8 | |
| Q1, Q3 | 1.7, 2.0 | 1.7, 2.0 | 1.7, 2.0 | |
| Range | 1.0–5.0 | 1.3–2.7 | 1.0–5.0 | |
| Estrogen receptor status | 0.0177b | |||
| Negative | 2949 (35.8%) | 507 (35.1%) | 3456 (35.7%) | |
| Positive | 5201 (63.2%) | 934 (64.6%) | 6135 (63.4%) | |
| Missing | 84 (1.0%) | 4 (0.3%) | 88 (0.9%) | |
| Progesterone receptor status | 0.0004b | |||
| Negative | 3487 (42.3%) | 680 (47.1%) | 4167 (43.1%) | |
| Positive | 4638 (56.3%) | 757 (52.4%) | 5395 (55.7%) | |
| Missing | 109 (1.3%) | 8 (0.6%) | 117 (1.2%) | |
| Human epidermal growth factor 2 status | <0.0001b | |||
| Negative | 2662 (32.3%) | 883 (61.1%) | 3545 (36.6%) | |
| Not done/unknown/missing | 4952 (60.1%) | 387 (26.8%) | 5339 (55.2%) | |
| Positive | 620 (7.5%) | 175 (12.1%) | 795 (8.2%) | |
| Anthracycline received | <0.0001b | |||
| No | 1705 (20.7%) | 669 (46.3%) | 2374 (24.5%) | |
| Yes | 6529 (79.3%) | 761 (52.7%) | 7290 (75.3%) | |
| Missing | 0 (0.0%) | 15 (1.0%) | 15 (0.2%) | |
| Cyclophosphamide received | <0.0001b | |||
| No | 1705 (20.7%) | 535 (37.0%) | 2240 (23.1%) | |
| Yes | 6529 (79.3%) | 895 (61.9%) | 7424 (76.7%) | |
| Missing | 0 (0.0%) | 15 (1.0%) | 15 (0.2%) | |
| CMF received | ||||
| No | 8234 (100%) | 1311 (90.7%) | 9545 (98.6%) | |
| Yes | 0 (0%) | 134 (9.3%) | 134 (1.4%) | |
| Paclitaxel or capecitabine only received | ||||
| No | 6529 (79.3%) | 910 (63.0%) | 7439 (76.9%) | <0.0001 |
| Yes | 1705 (20.7%) | 535 (37.0%) | 2240 (23.1%) | |
Because of rounding, percentages may not total 100
ECOG Eastern Cooperative Oncology Group
a
Body surface area is reported for those with available data only (n = 9559)
b
By Chi Square testing
c
By Kruskal Wallis testing